Document 6562965

KPTI Pipeline
Preclinical
Phase 1
Later Stage
Selinexor (KPT-­‐330)
Registra&on-­‐Directed
NHL, DLBCL, Richter’s, MM, WM
Hematological Malignancies
AML
T-­‐Cell
CML
ALL
Elderly AML – 2nd -­‐Line Richter’s – 2nd -­‐Line DLBCL– 3rd -­‐Line MM/WM: combo with low dose dexamethasone
Solid Tumors
Phase 2
Gynecological Malignancies Advanced Tumors
Sof Tissue or Bone Sarcomas (Food Effect Study)
Glioblastoma Mul&forme
Metasta&c Prostate
Squamous H&N, Lung, Esoph
Wound Healing KPT-­‐350, Related SINE Compounds
Inflamma&on, Autoimmune & An&-­‐viral
PAK4 Inhibitors Oncology
H1 2015 H1 2015 Mid 2015
We also plan to ini&ate up to two addi&onal registra&on-­‐directed trials in hematological or solid tumor indica&ons in late 2014 or early 2015
Current
Planned
3
3
©2014 – Karyopharm Therapeutics, Inc. | Confidential & Proprietary